The USER Study: A Chart Review of Patients Receiving a 0.2 µg/day Fluocinolone Acetonide Implant for Diabetic Macular Edema
Sign Up to like & getrecommendations! Published in 2018 at "Ophthalmology and Therapy"
DOI: 10.1007/s40123-018-0155-5
Abstract: IntroductionTo determine anatomical, functional, and intraocular pressure (IOP) responses to diabetic macular edema (DME) treatments pre- and post-0.2 µg/day fluocinolone acetonide (FAc) implant administration compared with baseline and the preceding 3 years.MethodsThis was a retrospective, chart review,… read more here.
Keywords: post fac; treatment; fac implant; day ... See more keywords
Two-year interim safety results of the 0.2 µg/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study
Sign Up to like & getrecommendations! Published in 2020 at "British Journal of Ophthalmology"
DOI: 10.1136/bjophthalmol-2020-315984
Abstract: Background The 0.2 µg/day fluocinolone acetonide (FAc) implant delivers continuous, low-dose, intravitreal corticosteroid for the treatment of diabetic macular oedema (DMO). This ongoing, 3-year, observational clinical trial provides long-term, ‘real-world’ safety results for the FAc… read more here.
Keywords: post fac; treatment; fac implant; year ... See more keywords